Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia-Reply.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

1. Molecularly targeted therapy and immunotherapy in leukemias.Journal of hematology & oncology · 2026
   Review
2. Editorial: Allogeneic haematopoietic stem cell transplantation for children with acute lymphoblastic leukaemia in the era of immunotherapy.Frontiers in pediatrics · 2022
   Article
3. Advanced nanoparticles that can target therapy and reverse drug resistance may be the dawn of leukemia treatment: A bibliometrics study.Frontiers in bioengineering and biotechnology · 2022
   Article

Corrections and comments

• Comment on
  Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia.2021

Authors and funding

3 authors at 3 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as